A total of 440 healthy adults are being enrolled in the trial across 11 investigational sites in the US, the two drugmakers said. The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's pandemic adjuvant technology.